The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Wiley Brian since 2014.
The trader's CIK number is 1566492.
At the time of the last reporting, Wiley Brian was the VP of Business Development of Newlink Genetics Corp. (stock ticker symbol (NLNK)).
Also see all insider trading activities at Newlink Genetics Corp.
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2016 | (NLNK) | 0 | $0 | 1,295 | $44,975 | 0 | $0 |
2015 | (NLNK) | 0 | $0 | 50,000 | $2,109,440 | 50,000 | $589,497 |
2014 | (NLNK) | 0 | $0 | 55,000 | $1,808,319 | 55,000 | $648,445 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2016-01-05 | (NLNK) | Sale | 1,295 | 34.73 | 44,975 |
2015-03-02 | (NLNK) | Option Ex | 20,000 | 11.79 | 235,799 |
2015-03-02 | (NLNK) | Sale | 20,000 | 45.11 | 902,140 |
2015-02-17 | (NLNK) | Option Ex | 10,000 | 11.79 | 117,899 |
2015-02-17 | (NLNK) | Sale | 10,000 | 40.07 | 400,700 |
2015-01-02 | (NLNK) | Option Ex | 20,000 | 11.79 | 235,799 |
2015-01-02 | (NLNK) | Sale | 20,000 | 40.33 | 806,600 |
2014-02-03 | (NLNK) | Option Ex | 20,000 | 11.79 | 235,799 |
2014-02-03 | (NLNK) | Sale | 20,000 | 36.41 | 728,199 |
2014-01-21 | (NLNK) | Option Ex | 10,000 | 11.79 | 117,899 |
2014-01-22 | (NLNK) | Option Ex | 5,000 | 11.79 | 58,949 |
2014-01-21 | (NLNK) | Sale | 10,000 | 35.01 | 350,080 |
2014-01-22 | (NLNK) | Sale | 5,000 | 35.64 | 178,200 |
2014-01-15 | (NLNK) | Sale | 10,000 | 30.00 | 300,000 |
2014-01-13 | (NLNK) | Option Ex | 10,000 | 11.79 | 117,899 |
2014-01-13 | (NLNK) | Sale | 10,000 | 25.18 | 251,840 |
2014-01-15 | (NLNK) | Option Ex | 10,000 | 11.79 | 117,899 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Wiley Brian (VP of Business Development of Newlink Genetics Corp at the time of this reporting) see the Securities and Exchange Commission (SEC) website.